Umbilical-Derived Stem Cell Therapy (Only for Local Injection)
Important Regulatory & Legal Notice (Florida & U.S.)
• There are currently no FDA-approved stem cell products (including umbilical-derived MSCs) for orthopedic, neurologic, autoimmune, anti-aging, or wellness use.
• Any non-hematologic use is considered investigational / experimental.
• Products must not be marketed as treating or curing disease.
• At EverHealth, therapy is provided only under physician oversight, using GMP-tested biologic materials from authorized sources, and only after thorough risk-benefit review and signed informed consent.
• We comply with Florida medical board guidance and U.S. FDA regenerative-medicine enforcement policies.
Disclaimer: Stem cell therapy at EverHealth is investigational and is not FDA-approved to diagnose, treat, cure, or prevent any disease. Results vary. Risks and alternatives will be discussed prior to treatment.
This transparency ensures patients receive innovative care delivered ethically, responsibly, and safely.
What Evidence Exists for Local (Targeted) MSC Injection?
Local UC-MSC injections have been studied though still considered investigational primarily in orthopedic and tissue-healing settings. Published human studies suggest potential benefit in the following area when injected locally under sterile technique:
Knee Osteoarthritis & Cartilage Degeneration
Randomized and prospective studies show UC-MSC injections may:
• improve pain and function scores
• support cartilage quality on MRI
• reduce inflammatory signaling
Examples of peer-reviewed evidence include:
• Lamo-Espinosa et al., Transplantation (2016) MSC injection improved knee OA pain and functional outcomes vs control.
• Gupta et al., Stem Cells International MSC therapy associated with symptomatic improvement and cartilage benefit
Repair of Tendons and Soft Tissues (Investigational)
Pilot and preliminary studies indicate possible assistance in tendon recovery, encompassing:
- Rotator cuff pathology
- Achilles tendinopathy
- Chronic tendon degeneration (evidence remains early-stage and diverse).
Recovery after surgery or injury (under investigation)
Some studies indicate less pain, enhanced mobility, and improved tissue healing markers subsequent to the use of MSC in orthopedic recovery contexts.
Localized Inflammatory Joint Conditions (Investigational)
Small controlled and uncontrolled trials suggest possible benefit in reducing pain, stiffness, and functional limitation via immune-modulating effects.
What’s Happening Biologically?
Umbilical-derived MSCs do not “become” new tissue in humans in routine clinical practice. Instead, current science suggests their benefit is primarily paracrine-mediated, meaning they release growth factors, extracellular vesicles, and cytokines that may:
- support native repair cells
- calm inflammatory signaling
- improve local tissue environment
- promote angiogenesis and matrix remodeling
This is mechanistic and investigational not a guaranteed clinical outcome.
Safety, Sourcing & Quality Standards
At EverHealth, we use properly sourced biologic materials only from vetted, qualified suppliers with:
- GMP-level processing
- Donor screening & serology testing
- Sterility & Endotoxin testing
- Documentation & lot traceability
- Chain-of-custody control
- Temperature-controlled storage
Patients are counseled regarding:
- Risks of infection
- Allergic/immune reactions
- Potential lack of benefit
- Possibility of worsening symptoms
- Need for staged or adjunctive care
- Your care is always physician-directed and medically supervised.
Our Promise at EverHealth
- Physician-directed care
- Transparent risk discussion
- Evidence-anchored decision-making
- Vetted sourcing
- Informed consent
- Realistic expectations
- This is responsible regenerative medicine.
What About IV (Systemic) Stem Cell Infusion?
We believe in science first and honesty always.
There are human clinical trials using IV MSC infusions, sometimes described as stem cell IV infusion or systemic MSC Therapy, including autoimmune, inflammatory, pulmonary, and metabolic research. Some studies demonstrate reductions in CRP and inflammatory cytokines and improvements in functional outcomes particularly in:
- autoimmune-related inflammatory disease
- graft-versus-host disease
- certain pulmonary inflammatory settings
However:
- Systemic IV MSC infusion remains earlier-stage research.
- Long-term safety & optimal dosing remain under study.
- No IV MSC product is FDA-approved for general clinical use.
- Risks may include immune reaction, infusion response, infection risk, or theoretical clotting/embolic risks.
Therefore, EverHealth presently limits MSC use to local, targeted injection under medical oversight, unless part of a formal approved research environment.
Who May Be Considered for Local Experimental MSC Therapy?
Patients seeking:
- orthopedic pain support
- cartilage health support
- tendon or soft-tissue recovery support
- anti-inflammatory modulation in a localized site
after failing conservative therapy may be considered following physician evaluation.
We work collaboratively with orthopedic, rheumatology, and specialty partners as appropriate.
Frequently Asked Questions
Is stem cell therapy FDA-approved?
Are results guaranteed?
No. Outcomes vary and may be modest or absent.
Is this covered by insurance?
Typically no experimental therapy is self-pay.
Is the material ethical & safe?
We only use screened, ethically obtained umbilical-derived biologics processed in regulated facilities.
Can I use this instead of surgery?
This is not a surgical substitute and should be discussed with your surgeon.